The single-arm trial met its primary end point of complete response (CR) at any time, exceeding historic and contemporary ...
Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 140.0 million in the second quarter of 2026 (Q2 2025: NOK 135.6 million), and an adjusted EBITDA of NOK 27.2 million (Q2 2025: ...
Data reinforce durable responses, bladder preservation, low rate of disease progression, and favorable safety and tolerability in patients with high-risk, BCG-unresponsive non-muscle invasive bladder ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results